Designed to help Canadians find investment solutions to the two big problems they’re facing: low interest rates and volatile stock markets, the Income Investor was chosen by The Globe and Mail as one of the top five investment newsletters in Canada. If you need income from investments with minimal risk, the Income Investor covers all types of income securities including income trusts, preferred shares, high-yielding common stocks, bonds, mutual funds, exchange-traded funds, and GICs. Any security that generates cash flow is fair game for our experts.

Edited and published by Gordon Pape. Editor: Mike Keerma.

With Gavin Graham, Shawn Allen, Adam Mayers, & Paul Bamford.

Recent Issues

tii2512 (June 26, 2025)

Spinoffs provide extra value… This month’s Top Pick: Haleon plc… Gavin Graham updates Watts Water Systems, Johnson & Johnson, Boardwalk REIT, Slate Grocery REIT, iShares MSCI UK ETF… Balanced Portfolio holds steady… Gordon Pape updates Algonquin Power & Utilities

tii2511 (June 12, 2025)

What’s safe?… Inflation defense… Adam Mayers updates Corby’s… New Harvest ETF worth a look

tii2510 (May 22, 2025)

Dividend cuts not always bad… This month’s Top Pick: Enghouse Systems… Gavin Graham updates The Keg Royalty Income Fund, Organon, Minto Apartment REIT… Gain for High-Yield Portfolio… Invest in Canada… Gordon Pape updates BMO, Russel Metals

tii2509 (May 7, 2025)

BIP worth a look… Grocery REITs offer dividends and safety… Adam Mayers updates Hydro One… Gavin Graham updates Allied Properties REIT… Your Questions: Taxing options

tii2508 (April 24, 2025)

Potomac fever… A primer on basis trading… Playing defense… Gavin Graham’s Top Pick: Cogeco Inc… Gavin Graham updates Artis REIT… Your Questions: Sold US house

tii2507 (April 10, 2025)

Pfizer’s woes create opportunity… A high-yield, high-risk stock… Adam Mayers updates Digital Realty Trust… Gordon Pape updates P …

tii2506 (March 27, 2025)

Investing in convenience… This month’s Top Pick: Fomentos Economico Mexicano… Gavin Graham updates CK Hutchison, Calian Group, Leon’s Furniture, Stella-Jones… Utilities, telecoms offer tariff protection… Adam Mayers updates BMO Equal Weight Utilities Index ETF… Three ETFs for uncertain times… Your Questions: RRIF withdrawals

Older issues

Recent Updates

Boardwalk REIT (TSX: BEI.UN)

Boardwalk is the largest apartment REIT in Alberta and Saskatchewan, with 64.3% of its units in Alberta. As Alberta has no rent controls, Boardwalk is able to benefit from increases in rents driven by market forces. The province is the cheapest major urban market for rents and enjoys inward migration from more expensive provinces.


Buy


Watts Water Systems (NYSE: WTS)

Watts Water is a provider of market-leading brands in water solutions, with annual sales of $1.8 billion in 2021. Its divisions provide the highest level of performance in the safeguarding of water systems, driven by code and certification, address energy efficiency needs by offering the most efficient conversion of energy sources into heat and hot water, and deliver drainage and pre-treatment systems that help with water conservation projects.


Buy


UK iShares MSCI ETF (NYSE: EWU)

This ETF invests in the UK’s FTSE100 Index, which consists mostly of large-capitalization U.K.-based companies. Launched in March 1996, it has US$3 billion in assets under management and has a reasonable MER of 0.5%.


Buy


Algonquin Power & Utilities Corp. (TSX, NYSE: AQN)

Algonquin’s transition into a conventional utility is paying off. The company reported first-quarter adjusted earnings of $111.6 million ($0.14 a share), up from $80.1 million ($0.11 a share) in the same period last year. Note that the company reports in US dollars.

“The company recorded a constructive first quarter of 2025 with notable year-over-year improvements in our key financial metrics,” said CEO Rod West, who took over the job in March. “Our results were solid, reflecting the strength of our core regulated utility operations.”


Hold


Johnson & Johnson (NYSE: JNJ)

Johnson & Johnson (JNJ) is one of the largest healthcare companies in the world. It employs over 120,000 people in its two divisions, Pharmaceutical and MedTech. It spun off its consumer healthcare division in 2023, naming it Kenvue. About 64% of its $88.8 billion in 2024 revenues came from its pharmaceutical division, while the remaining 36% was from its MedTech operations.


Buy